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Abstract: Pertussis (‘whooping cough’) is a severe respiratory tract infection that primarily affects
young children and unimmunised infants. Despite widespread vaccine coverage, it remains one
of the least well-controlled vaccine-preventable diseases, with a recent resurgence even in highly
vaccinated populations. Although the exact underlying reasons are still not clear, emerging evidence
suggests that a key factor is the replacement of the whole-cell (wP) by the acellular pertussis (aP)
vaccine, which is less reactogenic but may induce suboptimal and waning immunity. Differences
between vaccines are hypothesised to be cell-mediated, with polarisation of Th1/Th2/Th17 responses
determined by the composition of the pertussis vaccine given in infancy. Moreover, aP vaccines
elicit strong antibody responses but fail to protect against nasal colonisation and/or transmission, in
animal models, thereby potentially leading to inadequate herd immunity. Our review summarises
current knowledge on vaccine-induced cellular immune responses, based on mucosal and systemic
data collected within experimental animal and human vaccine studies. In addition, we describe key
factors that may influence cell-mediated immunity and how antigen-specific responses are measured
quantitatively and qualitatively, at both cellular and molecular levels. Finally, we discuss how we
can harness this emerging knowledge and novel tools to inform the design and testing of the next
generation of improved infant pertussis vaccines.
Keywords: Bordetella pertussis; whooping cough; T-cells; B-cells; vaccination; immunity; correlate-of-
protection; antigen-specific; epitope; colonisation
1. Introduction
1.1. The Story so Far
Bordetella pertussis (Bp) is a gram-negative bacterium that causes pertussis (‘whooping
cough’), an acute respiratory tract infection which disproportionally affects young children,
particularly unimmunised infants [1,2]. Up until the early twentieth century, whooping
cough was one of the most important causes of mortality in children under 5 years; the
introduction of the first whole-cell pertussis vaccine (wP), consisting of detoxified killed
whole Bp, within national immunisation programmes in the 1940–50s was therefore hailed
as a success story [3,4]. However, due to its perceived neurological side effects and broader
reactogenicity, caused by the multiple bacterial antigens present, including highly immune-
stimulatory cell wall component lipooligosaccharide (LOS) and other virulence factors,
vaccine uptake subsequently began to decline [5]. As such, a safer alternative was de-
veloped, the acellular pertussis (aP) subunit vaccine, which was shown to confer equal
protection against severe symptomatic disease [6]. Several aP vaccines are available differ-
ing by the number of Bp antigens that they contain, their dose, as well as their formulation;
currently licenced variations contain alum adjuvant and between one to five purified,
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stabilised, and chemically or genetically modified (detoxified) pertussis antigens, including
pertussis toxin (PT, at least), filamentous haemagglutinin (FHA), pertactin (PRN), and
fimbrial proteins 2 (FIM2) and 3 (FIM3).
From the 1990s, therefore, aP began to be rolled out globally by the World Health
Organisation (WHO) and was incorporated into the primary immunisation schedule of
most high-income countries (HICs) [7,8]. Despite high vaccine coverage rates (especially
in HICs), however, there has been a resurgence in Bp disease worldwide and it remains
a primary cause of vaccine-preventable death [9,10]. Recent models have indicated that
there were 24.1 million pertussis cases and 160,700 deaths in children younger than 5 years
worldwide in 2014, with the highest burden in sub-Saharan Africa, although these are
estimates given the paucity of pertussis epidemiological data to date [11]. In many low-
to-middle-income countries (LMICs), the suboptimal pertussis control is thought to be
primarily due to limited access to vaccines and inadequate healthcare resources, with
poor diagnostic tools [12–14]. In HICs, the situation is more complex, and several rea-
sons have been postulated for the increased reporting, including improved diagnostics,
enhanced surveillance, changes in immunisation strategy and administration schedules,
differences in vaccine composition and immune responses induced, and antigenic variation
in the circulating strains of Bp due to vaccine selection pressure, reviewed extensively
elsewhere [4,10,15,16].
The most plausible explanation is the switch in infant primary immunisation from
wP to aP vaccines, which has been linked to less effective protection (particularly against
colonisation, infection and transmission) and waning immunity [10,17–21]. The data to
support this hypothesis primarily stems from both epidemiological studies and animal
infection/transmission models. Infection in predominantly aP-vaccinated settings peaks in
two age groups: (1) infants too young to have received the primary immunisation schedule
and who should, therefore, benefit from herd immunity, suggesting that sterilising immu-
nity is not achieved through immunisation; colonisation (often asymptomatic) can thus still
occur, facilitating bacterial transfer to vulnerable, unprotected cohorts (2) adolescents and
adults, although the clinical presentation is less severe, indicating that different specific
long-term immune memory is elicited by the vaccines, with pertussis-specific immunity
waning more rapidly following aP vaccination. Observational studies have shown that
older children primed with aP compared to wP vaccines in infancy had a 2-to 5-fold greater
risk of pertussis diagnosis [22–24]. Moreover, a US case control study demonstrated that,
among adolescents who have only received DTaP vaccines in childhood, vaccine effec-
tiveness following Tdap booster was 68.8% during the first year after vaccination, rapidly
declining to 8.9% by≥4 years after vaccination [25]. Nevertheless, even wP vaccines do not
seem to establish as effective or long-lasting immunity as natural infection [26]. Pertussis
outbreaks in these two cohorts have, therefore, led to the introduction of multiple boosters
in some countries (particularly in the primary school and adolescent age groups) and
routine maternal vaccination in pregnancy to protect the new-born in early life, prior to
their first priming vaccine dose [27,28].
1.2. Differences in Vaccine Composition and Host Immune Responses Go Hand-in-Hand
Differences between vaccines are multifactorial and interrelated. Key contributing
factors are the underlying qualitative and quantitative immunological mechanisms that
mediate efficacy and longevity of vaccine-induced protection, particularly at the respiratory
mucosal interface. Animal models have shown that memory CD4+ T-cells of T-helper
(Th-)1 and Th17 phenotype facilitate long-term protection, which are elicited by natural
infection as well as immunisation with wP [29–32]. In contrast, aP vaccination is associ-
ated with a predominant Th2 response in humans [33–37]. Beyond Th-cell polarisation,
other qualitative changes in cellular responses may result in suboptimal and/or shorter
efficacy [21,38–41]. For instance, given that wP vaccines appear to prevent colonisation
in animal models, they may induce immune responses that home to and/or act more
effectively at the mucosal interface compared to aP vaccines [17,31,42–44].
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These mechanisms are, in part, shaped by the choice of adjuvant in either vaccine.
The more durable priming upon wP vaccination might especially be due to the highly
immunostimulatory LOS, operating as an adjuvant by activating innate immune cells,
for example, via toll-like receptor (TLR-)4 [6,26,45]. By contrast, aP vaccines primarily
contain the less reactogenic adjuvant, alum, which potentially contributes to the limited
duration of effective protective immunity against pertussis. Other factors related to vaccine
composition may further influence the differential immune responses. One example is the
chemically detoxified PT contained in the aP vaccine, which may have altered antigenicity
and could potentially impact vaccine efficacy [1,16]. Furthermore, given that the wP
vaccine contains >3400 open-reading frames, whereas the aP vaccine includes only five
or fewer Bp proteins, it is likely that the former elicits a broader reactivity and targets
additional surface antigens, some of which might be of particular relevance and linked
to superior vaccine performance [46,47]. This potentially underlies differences observed
in the breadth of antibody responses and/or functional antibodies induced: primarily
PT-neutralising compared to a combination of neutralising, agglutinating and opsonising
antibodies following aP and wP vaccines, respectively [48–50]. However, to date, the
extent and targets of T-cell immunity in the context of natural infection, clinical disease
or vaccination have not been comprehensively defined. Of note, comparisons of vaccine
composition (and immune responses elicited) are hampered by the heterogeneity of aP
vaccine formulations, immunisation strategies and administration schedules.
Beyond this, antigenic drift may potentiate reduced vaccine effectiveness and waning
of Bp immunity, particularly in settings with widespread aP use [46,51–53]. Novel circu-
lating Bp strains have evolved, containing mutations and/or deletions of key epitopes
or antigens; this is secondary to pathogen adaptation to natural or, most likely, vaccine
selection pressures, with subsequent pathogen escape [46]. Examples include strains with
polymorphisms of the PT gene (leading to enhanced production of this protein), or which
lack the PRN gene (demonstrating increased fitness and/or prolonged infection times,
given that PRN is a key target of opsonising antibodies), primarily in the context of aP-
containing immunisation schedules [16,48,54,55]. However, data on the impact of these
mutations and similar genetic modifications on vaccine-mediated efficacy, particularly
in settings of PRN-deficient Bp strains are conflicting and further studies are urgently
required [56]. Finally, whether specific T-cell immune pressure has resulted in the observed
genetic variability of these strains is yet to be fully elucidated [46,53].
1.3. Evidence for the Importance of Cellular-Mediated Immunity
No clear correlate-of-protection (CoP) against pertussis disease has been identified
which could inform vaccine development and licensure [57,58]. Pertussis-specific serum
antibody response is important in limiting severity of disease [59] and to some extent
infection, however, the currently available antibody assays are insufficient to represent
a CoP [60–62]. Cell-mediated immunity (CMI) is increasingly thought to play a key role
in both vaccine efficacy and longevity of protection, via effector mechanisms as well as
influence on magnitude, quality and longevity of the broader immune response [41,63,64].
High antibody levels are elicited by both vaccines, although less is known about potential
qualitative differences in antibody responses, which may be T-helper cell related. Vaccine-
induced protection against disease persists even after circulating antibody titres have
waned and/or are absent at the time of challenge [6,21,65]. Repeated pertussis immu-
nisation of B-cell knockout (BKO) mice resulted in partial protection. Moreover, mice
depleted of CD4+ T-cells after immunisation but before aerosol challenge, who therefore
had normal levels of specific antibodies, were not optimally protected [66]. Complete
protection was reconstituted by transfer of pertussis-immune B-cells; reconstituted BKO
mice had little if any detectable anti-pertussis antibodies [66]. Coupled with the dual
nature of Bp as an intracellular and extracellular pathogen, these findings already suggest
a key role for (primarily CD4+) T-cells and B-cells in protective immunological memory,
with both cell types providing significant functions other than specific antibody produc-
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tion [36,41,63–67]. Furthermore, emerging evidence from studies of both pertussis and
other respiratory pathogens indicates that the local tissue-resident memory T-(TRM) cells
that accumulate in respiratory tissue following mucosal infection may be crucial for long-
term immunity [42,43]; elucidating their phenotype and functional capacity in the context
of vaccination is therefore critical.
This review will summarise current knowledge on the nature, frequency and breadth
of antigen-specific cellular responses induced following childhood pertussis immunisation.
In particular, we will address how these mechanisms shape the ability of aP compared to
wP vaccines to protect against infection/transmission and to induce long-lived immune
memory. Our focus will be on the (pertussis-specific) T-cell compartment, as measured in
peripheral blood and/or at the level of the respiratory mucosa, including its interrelation-
ship with B-cell-mediated responses and innate immunity (Figure 1a,b).
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2. What Have We Learned about Vaccine-Induced T-Cell-Mediated Immunity from
Animal Models?
2.1. The Mouse Model
2.1.1. Systemic Responses
Seminal mouse studies by Mills et al. first highlighted the critical role of T-cells in
the direct protection against Bp infection, by showing that mice able to clear the infection
generated robust antigen-specific T-cell responses in the absence of a detectable serum
antibody response [29,68]. Furthermore, adoptive transf r of spleen cells or purifi d
CD4+ T-cells (but not CD8+) from convalescent mice conferred protection against Bp-
respiratory challenge in nude or irradiated mice resulting in bacterial clearance from the
lung, [32,63,69]; these cells were polarized to Th1 and Th17 phenotypes, although the
greatest protection was observed when both cell-types were transferred [67]. Injection of
serum from protected animals, however, only marginally reduced bacterial loads [29,67,68].
Subsequent mechanistic studies using mice defecting in individual cytokines and/or re-
ceptors confirmed the important ole of Th1 and Th17-cells in recruiting phagocytes to the r s-
piratory tract, bacterial clearance and protection against subsequent challenge [29,67,69–72].
Infection in IFN-γ−/− and IFN-γ receptor−/−mice led to atypical or disseminated disease,
while IL-17−/−mice demonstrated significantly increased Bp load in lung samples, reduced
CXCL1 production and impaired neutrophil recruitment post-Bp challenge [67,69,73]. Bp
virulence factor, adenylate cyclase toxin, was shown to activate caspase-1/NLRP3 inflamma-
some, thereby promoting IL-1β production by murine macr ph es or dendritic cells and
subsequent bacter al clearance [74]. Bp pathogenesis was significantly exacerb ed n IL-1R
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type I-defective mice [74,75]. In contrast, primary infection with Bp was not significantly
different between IL-4−/− and wild-type mice, suggesting that Th2-CMI is not essential for
protection [67].
Beyond this, the mouse respiratory infection model has proven a useful tool for
the evaluation of vaccine-induced immunity, since bacterial clearance from lungs follow-
ing exposure to Bp correlates with vaccine efficacy [70,71,76,77]. After exposure to a Bp
respiratory challenge, convalescent mice and those immunised with wP eliminated the
bacterial infection significantly faster than mice immunised with aP [63]. Consistent with
natural infection, effective pertussis immunisation in mice has been shown to depend
on induction of CMI, with no protection established in mice lacking all T-cells or CD4+
T-cells [66]. Furthermore, polarisation of Th-cells occurs, determined by infant prim-
ing [63,67]. Th1/Th17 subsets coordinate wP-induced immunity [45,67,71] with a larger
contribution by IFN-γ-secreting cells compared to Th17. In contrast, aP immunisation
elicits Th2/Th17 responses [67,71,78]; however, IL-17A plays an essential role, with failure
of protective immunity in IL-17A defective mice, while IL-4 is unnecessary for bacterial
clearance [67,78].
2.1.2. Mucosal Responses
In addition to characterising systemic immune responses, the murine model has
enabled mechanistic studies of CMI at the mucosal level, in both the upper and lower
airways. Following Bp infection, mice express IL-17, IL-6, and IL-8 homologs in the lungs
consistent with a local Th17 response [79].
Antigen-specific tissue resident memory cells (TRMs) have garnered significant interest
recently as they are increasingly thought to be critical in establishing protection against rein-
fection at the mucosa and long-term immune memory against different pathogens [26,43,80].
Specifically, IL-17- and IFNγ-secreting CD69+CD4+ TRM cells were shown to accumulate
in the lungs of mice during pertussis infection [81]. The same cell phenotype significantly
expanded in both lungs and nasal tissue after Bp challenge and reinfection of convales-
cent [42,43,81,82] or wP- but not aP-immunised mice [83]. Sphingosine-1-phosphage receptor
agonist FTY720 (fingolimod) blocks T- and B-cell migration from lymph nodes to the circu-
lation without impairing their activation; FTY720 administration to mice during primary
infection or wP immunization resulted in reduced homing of central memory T- and B-cells
to the lungs, which was further associated with impaired Bp clearance. Conversely, treatment
with FTY720 before re-challenge did not affect the local expansion of TRM cells and hence
the associated rapid clearance of the secondary infection. Therefore, wP vaccination of mice
elicited protection against lung and nasal colonisation whereas aP immunisation failed to
protect in the nose. Similarly, adoptive transfer of lung CD4+ TRM cells from convalescent
or wP-immunised mice conferred protection in naïve mice [83]. Previous infection, however,
induced the most persistent protection against nasal colonisation and this correlated with
potent induction of nasal tissue TRM cells, especially those secreting IL-17 [42,81,83]. Expan-
sion of the TRM population has been observed following select next-generation vaccines,
including intranasal live-attenuated BPZE1, outer membrane vesicle (OMV) vaccines, and
intranasal administration of aP vaccine with TLR9 and stimulator of interferon genes (STING)
agonists (Table 1).
As well as CD4+ TRM cells, pulmonary γδ T-cells may be another key player in
mucosal immunity. They enable both an early source of innate IL-17, thereby promoting
antimicrobial peptide production, as well as adaptive immunological memory against Bp,
analogous to conventional αβ T-cells, through antigen-specific Vγ4 cells. γδ T-cells with a
TRM phenotype (i.e., CD69+CD103+) were shown to expand in the lungs during infection
with Bp and proliferate rapidly after rechallenging convalescent mice [82]. Their role in
vaccine-induced protection is still being explored.
Finally, although these findings confirm the contribution of local mucosal responses
to effective bacterial clearance and prevention of colonisation, to date a detailed characteri-
sation of transmission dynamics has not been possible in mice. Nevertheless, Scanlon et al.
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recently reported the first study of Bp transmission in murine neonates, which may prove a
valuable tool in future mechanistic research on vaccine-induced immunity [84].
2.2. The Baboon Model
2.2.1. Colonisation and Transmission Studies
Comparison of published murine data is difficult, given the heterogeneity in ap-
proaches and methodology. Various mouse strains (e.g., BALB/c vs. C57Bl/6), immu-
nisation routes (e.g., intraperitoneal vs. intracerebral), vaccine doses, compositions and
regimens have been studied; moreover, different infectious challenge doses of varying
Bp strains were administered in different suspension volumes, either directly into mouse
nares, or as inhaled aerosol [48]. Most importantly, the murine challenge model does not
accurately recapitulate the natural disease course in humans. Instead, the baboon model
has been increasingly used to study both pertussis disease pathology and vaccine-induced
immune responses [85]. The baboon displays similar systemic symptoms (lymphocytosis,
hypoglycaemia) and respiratory characteristics (heavy respiratory colonization, parox-
ysmal cough, >2 weeks, aerosol transmission) to humans. Furthermore, immunological
mechanisms vary between mice and humans, for example TLR distributions and IgG
subclasses [86–88].
A series of studies in the baboon demonstrated that aP vaccination provides excellent
protection against severe disease but does not prevent colonisation, either following direct
challenge (Bp aerosol) or infection due to transmission (between vaccinated and naïve
subjects) [17,30,31,86,89–91]:
(a) Following direct challenge with Bp aerosol, wP- and aP-vaccinated baboons dis-
played similar initial nasopharyngeal colonisation, although the former group cleared
infection significantly faster than naïve and aP-immunised animals. Neither wP-
vaccinated, aP-vaccinated, nor convalescent baboons showed signs of severe respira-
tory or systemic disease.
(b) To evaluate whether vaccination prevents pertussis infection by natural transmission,
two aP-vaccinated animals and one unvaccinated baboon were housed together with
a directly challenged, unvaccinated baboon (who subsequently became infected). All
animals were colonised by 7–10 days, with no significant differences in peak levels
and kinetics of colonisation between naïve and aP-immunised baboons.
(c) To confirm that aP-vaccinated baboons are not only capable of being colonised but
can subsequently also transmit Bp to naïve contacts, aP-vaccinated animals were
challenged with Bp and placed in separate cages. After 24 h, a naïve animal was
added to each cage; both were infected by transmission from their aP-vaccinated
cage mates.
2.2.2. Systemic Responses
Characterisation of the phenotype of the baboon cellular compartment demonstrated
similar Th1/Th2/Th17 polarisation to the murine model. Long-lived Bp-specific Th17
and Th1-memory-cells were observed in convalescent animals >2 years post-infection
suggesting a role in immunological memory to pertussis. Similarly, CD4+ T-cells from wP-
vaccinated animals secreted IFN-γ but no IL-5; IL-17 secretion was between levels for naïve
and convalescent baboons, suggesting that wP vaccination induces similar, albeit weaker,
Th1 and Th17-memory responses to natural infection. aP-vaccinated baboons, however,
demonstrated a significant IFN-γ (similar to wP) and IL-5 response, consistent with skewing
toward Th1/2 memory, but no significant increase in IL-17 secretion, contrasting findings
in mice [30,31].
2.2.3. Mucosal Responses
At the mucosal level, primary pertussis infection is characterised by a transient in-
crease in IL-17, IL-6, IL-8 and other cytokines and chemokines associated with Th17
response and neutrophil activation in baboon nasopharyngeal samples [30,91]; analysis of
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the mucosal immune milieu (including cytokines and pertussis-specific antibody) following
aP versus wP vaccines is awaited. These findings suggest a plausible explanation for the
differences observed in the strength and persistence of protective immunity induced by the
aP or wP vaccines in humans, contributing to the recent pertussis outbreaks [16,31,88,91].
Nevertheless, the baboon model has disadvantages, not least the low numbers that can be
included in one experiment simultaneously, the time taken to breed each baboon (gestation
time of ~6 months) and poor availability of primate cell-markers.
2.3. Other Animal Models
Another promising model is the pig, given that its immune system more closely
resembles that of humans (when compared to mice), particularly TLR distributions and
responsiveness, Th17 characteristics and breast milk composition. Moreover, porcine sys-
temic and mucosal immune compartments are easily accessible, and many major markers
are available for use in porcine cells [92,93]. Pigs can be challenged with Bp and display a
wide range of respiratory and systemic symptoms, consistent with humans. Viable bacteria
can be re-isolated from bronchoalveolar lavage specimens and lung lesions for >10 days
after infection.
3. What Have We Learned about Vaccine-Induced T-Cell-Mediated Immunity from
Human Studies?
Results from human studies, across all age-groups, demonstrate the important contri-
bution of persistent pertussis-specific CMI to the long-term protection achieved by both
natural infection and vaccination; this may either be through its own effector mechanism or
by helping the antibody response [36,40,41]. T-cell responses, particularly of CD4+ memory
phenotype, specific for the vaccine components are induced that increase progressively
over the course of the primary infant schedule and are maintained for at least a few years,
in contrast to waning antibody titres [94,95].
Studies are heterogenous, however, particularly in their methodology and length of
follow-up, measuring different age groups, immunisation schedules and T-cell param-
eters, and further compounded by variations in vaccine formulations across different
settings [16,41]. Nevertheless, several key ideas emerge from the literature, albeit some-
times conflicting:
3.1. Distinct Patterns of Cellular Immune Responses Are Induced by aP vs. wP and Are Largely
Consistent with the Th1/Th2 Polarisation Observed in Animal Models
Natural infection and wP vaccination induce Th1-dominated responses corroborat-
ing findings in animal models [33,36]. Moreover, initial studies comparing magnitude of
CMI at different time points following aP vaccinations (primary or booster) versus either
natural infection or wP in children found an equally potent, and in some cases higher, re-
sponse [94,96–101]. In both aP-vaccinated and naturally infected infants, cytokine secretion
profiles demonstrated preferential induction of IL-2- and IFN-y-producing Th1 cells and
only low production of IL-10 [33,94,97]. In a separate study, following the primary DTaP
vaccine series, most participants mounted a positive proliferative T-cell response to the
PT and PRN antigens, with fewer positive responses to FHA and FIMs. One month after
booster DTaP vaccination (age 16 to 19 months), the cytokine profile was consistent with
Th1 skewing: a significant increase in IFN-γ production with the PT and FIM antigens, a
significant increase in IL-2 production with the PT, FHA, and PRN antigens, and lack of
significant IL-4 secretion with any of the antigens [102].
Furthermore, several Dutch studies have shown that replacement of wP by aP combi-
nation vaccines in infancy enhanced pertussis immune responses in the short term until
6 years of age, i.e., following the Dutch primary immunisation schedule (4 doses in the
first year of life) and then up to 2 years after the fifth DTaP booster given at preschool
age [39,98,99]. Specifically, DTaP booster vaccination induced more pertussis-specific CD4+
effector memory cells in preschool 4-year-old aP-primed compared to wP-primed children;
in contrast to previous studies, however, both Th1 and Th2-profiles were detected [99,103].
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Other groups more recently have similarly documented a mixed Th1/Th2 or a Th2-
skewed response in infant, child, adolescent and even in adult cohorts who have been
primed with aP compared to wP vaccines [36,37,104,105]. Ryan et al. examined cellular
responses in children immunised with a range of different aP and wP vaccines, concluding
that the mechanism of protection generated following aP immunisation was more heteroge-
neous, involving a mixed Th1 and Th2 cellular response [36]. These findings were observed
not only in response to the key pertussis vaccine antigens, but also to heterologous co-
administered tetanus toxoid. This suggests that the early cytokine profile is modulated by
the type of pertussis vaccine formulation [34,106]. Furthermore, differences in innate cells
and inflammatory signalling pathways triggered by wP versus aP vaccines may contribute
to the T-cell polarisation [107].
These differences in data may be explained by the heterogeneity of studies and their
methodology, as discussed previously. Van der Lee et al, however, attempt to reconcile
these conflicting findings by arguing that after 6 years of age, specifically following the
preadolescent Tdap booster vaccination (at 9 years), there is a shift in humoral and cellular
immunity [39]. While Th2 responses were similar between the aP- versus wP-primed
groups, preadolescents primed with wP vaccines during infancy had the more favourable
Th1-dominated immune response compared to aP-primed preadolescents for at least 1 year
after the booster vaccination. Polarisation toward a Th2 profile in aP-primed preadolescents
was caused by a decreased production of the Th1 cytokines (IFN-γ), and not by a higher
Th2 cytokine (IL-13) production. In keeping with this data, the shift in vaccine-specific
Th-cell pattern observed throughout childhood may reflect the developmental processes
occurring within the overall adaptive immune compartment. This global Th2 skewing may
be overcome by the unique composition of wP (i.e., presence of LOS) [104].
Characterisation of vaccine-induced antigen-specific IgG subclass responses follow-
ing different pertussis priming schedules further supports Th-subset skewing [38,108].
The IgG4 proportion was found to be significantly higher in aP- compared with wP-
primed children. This subclass does not bind complement and leads to a suboptimal
inflammatory response, with impaired phagocytosis and antimicrobial defence, hence
this may contribute to reduced protection against pertussis subsequently. These observa-
tions are consistent with murine data, given that IgG4 is functionally analogous to mouse
IgG1 [26]. By contrast, wP infant priming results in better opsonisation, phagocytosis,
and complement-mediated killing through the preferential induction of IgG1, despite
subsequent aP boosters [38,39,49].
3.2. Th-Cell Polarisation Established in Infancy Persists Even if Subsequent aP Boosters Are Given
in Adolescence and Adulthood
The current consensus is that childhood aP versus wP vaccines induce functionally
different patterns of T-cell responses to pertussis that remain skewed, even upon boosting
(by natural infection due to high pertussis circulation or following a single aP/dTaP vaccine
dose), up to several years or decades after the original priming [37,103,109]. aP-primed
children 4-years of age showed high Th1 and Th2 responses, more effector memory and
terminally differentiated CD4+ T-cells that remained unchanged or even decreased upon
the preschool booster, whereas those in wP-primed children were low but increased upon a
preschool booster vaccination [98,99,103]. Later in childhood, Th1 and Th2 cytokine levels,
and therefore Th1/Th2 ratios, remained unchanged before and after the preadolescent
booster vaccination in both groups of children [101]. This polarisation was still observed
even in adolescents primed with repeated aP vaccines during infancy [37,39,109]. Some
studies, however, have challenged these findings [110].
Of note, there is minimal data addressing potential issues around mixing aP/wP
vaccine formulations throughout childhood, and the subsequent impact on effectiveness or
duration of protection [111].
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3.3. Aside from Th Skewing, Infant Vaccine Type May Influence the Strength and/or Duration of
the Cellular Response
A recent comprehensive study demonstrated that adolescents originally primed with
aP have decreased capacity to respond to a booster immunisation in-vivo and diminished
proliferative capacity of T-memory cells in-vitro, potentially suppressed by a regulatory
cell population [109]. Similarly, in a pre-adolescent cohort, although the time since the last
booster vaccine was significantly longer for wP-versus aP-vaccinated individuals, their
proliferation capacity in response to antigenic stimulation was comparable; more children
also had a detectable cytokine response after wP compared to aP-vaccination [101]. A
further study documented persistence of T-cell memory against PT only in a minority
(36.8%) of children 5-years after aP priming. Differences in T-cell responses and potentially
long-term protection were demonstrated even between aP vaccine types, possibly explained
by variations in PT inactivation processes or excipient/adjuvant formulations [112]. These
findings corroborate recent epidemiological studies at the immunological level, indicating
that infant vaccination with wP induces longer lasting immunity than vaccination with
aP-vaccines. Indeed, repeated booster doses of the aP vaccine in children primed with the
same vaccine type has been shown to result in limited memory subset expansion and/or
progressively shorter duration of protection against disease [49,103,112].
3.4. Th17 Cells, Particularly of Tissue-Resident Memory Phenotype, Potentially Play an Important
Role in Pertussis Vaccine-Induced Immunity, Consistent with Animal Studies
There is indirect evidence of asymptomatic transmission of Bp from aP-vaccinated
to naïve individuals [20,113–115]. To date, however, little is known on human vaccine-
induced mucosal immune responses, the contribution of respiratory TRMs, particularly of
Th1 and Th17 phenotype, to protection against infection/disease and how this may vary
between vaccine types [42,116].
One previous study observed low systemic Th17 responses in both wP- and aP-
primed preadolescents, proposing that these responses may be far less pronounced upon
vaccination in humans than in animal models [37]. More recently, however, Antunes et al.
were the first to show that induction of antigen-specific Th17-cells following a pertussis
booster vaccine in adolescents was determined by their immunisation type given in infancy,
confirming results in the baboon (but not in mice). Applying a transcriptomics systems
vaccinology approach, they proposed that in comparison to wP priming, aP immunisation
results in higher production of IL-1 and IFN-β; this may in turn modulate the effect and
magnitude of TGF-β production which can block Th17 differentiation in aP donors [109].
As discussed previously, Th17 is important in clearance of infection at the level of
the mucosa, through both direct and indirect mechanisms [26,117,118]. Indeed, Th17
cells are key in promoting polymeric-IgR-mediated transport of secretory-IgA (sIgA) and
IgM into the airway [119]. Bp leads to potent pertussis-specific sIgA production in nasal
secretions which inhibits adherence of Bp to human respiratory epithelial cells, persisting
for several months after onset of symptoms [120]. Currently, however, there is conflicting
and limited evidence on the effect of mucosal IgA (and IgG) on pertussis disease severity,
infection/colonisation and vaccine-induced protection in both animal models and human
studies [44]. Moreover, little is understood about the kinetics of cytokines, particularly
those related to development and maintenance of Th17 response, and sIgA induced at the
mucosa following differential pertussis priming schedules. Knowledge is notably sparse
in younger paediatric cohorts, hindered by challenges in obtaining respiratory mucosal
samples, specifically lymphoid tissue, in this age-group.
3.5. Other T-Cell Subtypes May Play a Key Role in Vaccine-Induced Immunity
Most human vaccine studies have focussed on Th1/2 and, more recently, Th17 cel-
lular profiles. But other T-cell types may contribute to the differences in vaccine-induced
immunity and therefore require further attention. In addition to confirming the critical role
of pertussis-specific Th17 cells, Antunes et al. also demonstrated the potential importance
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of (a) IL-9 secreting T-cells in vaccine-mediated protection and (b) regulatory cells that may
inhibit T-memory-cell proliferation following pertussis booster vaccine in aP compared
to wP-primed infants [109]. This suggests the need to explore the potential contribution
of antigen-specific Th9 and T-regulatory(T-reg) cells in future studies. On the other hand,
previous groups found similarly low IL-10 secretion in both vaccine groups, a key cytokine
often involved in coordinating the T-reg response [37].
Another important T-cell type are T-follicular-helper (Tfh)-cells that bridge the T-
and B-cellular compartments and are crucial to establishing/maintaining long-lasting
highly specific memory [121,122]. Tfh promote survival, affinity maturation, and class
switch recombination of B-cells at the germinal centre (GC), as well as generation of B-
memory (Bm) and long-lived plasma cells (LLPCs). By modelling dynamic microarray gene
expression data, Deng et al. proposed that Tfh-cells are generated initially in the spleen
during Bp infection, and then migrate to the lung to participate in the GC reaction [123].
In humans, findings on the impact of different infant pertussis vaccines on the magni-
tude, maintenance and function of the Bm compartment are inconsistent and inconclusive,
potentially reflecting the heterogeneity of the interrelated T-cell data [38,96,98,100,124–127].
More recently, significantly fewer B-memory cell populations were measured post-booster
in older children who had completed aP versus wP infant immunisation [39]. Similarly,
the effect on pertussis-specific antibody avidity indices varies depending on infant vaccine
type, although results are conflicting [98,124,128]. These findings possibly indicate subop-
timal germinal centre T-cell/B-cell interactions at priming and subsequent differences in
vaccine-induced longevity and efficacy of protection. There is minimal data, however, on
the role of vaccine-induced pertussis-specific LLPCs in long-term protection, largely due
to the challenges in accessing these cells within the bone marrow where they primarily
reside long-term; this is compounded by our limited understanding of LLPC phenotype
and timing when they transit from secondary lymphoid organs to bone marrow [129].
Finally, although CD8−/− mice remained protected following aerosol Bp challenge, a
detailed characterisation of pertussis-specific CD8+ T-cell responses in humans remains un-
clear and would be informative [66]. This is given that Bp acts as both an intracellular and
extracellular pathogen, as well as the importance of IFN-γ, a key cytokine also produced by
cytotoxic cells. Rieber et al. quantified pertussis-specific CD8+ T-cell activation following
adolescent aP booster, demonstrating an increase in peripheral CD8+CD69+ activated
pertussis-specific memory T-cells four weeks after vaccination, regardless of infant prim-
ing [110]. Other studies in both convalescent and vaccinated participants have similarly
identified pertussis-specific CD8+memory T-cells, which may contribute to protection
against clinical pertussis [103,130].
3.6. The Human Challenge Model May Help to Address Gaps in Knowledge, Particularly on
Mucosal Immunity
Recently, a first-in-human controlled infection model (CHIM) has been developed.
Subjects were challenged by intranasal inoculation: the dose was gradually escalated
from 103 colony forming units (CFU) (none colonised) to 105 CFU (80% colonised). At
least a three-fold rise in serum anti-PT -IgG level was observed compared to baseline
by day 28 in 9/19 colonised subjects but not in uncolonised participants [131,132]. This
demonstrates that safe, deliberate induction of asymptomatic Bp colonisation is possible
and induces a systemic immune response. Both blood and mucosal samples are being
collected for analysis and results are urgently awaited. CHIM is a valuable tool to further
explore Bp colonisation and associated immune responses in natural infection and vaccine
development; nevertheless, due to ethical and safety concerns, challenge can only be
achieved in adult cohorts. One possible practical solution in the paediatric age-group is to
contextualise adult controlled-infection data within infant vaccine studies, linking mucosal
responses induced by infection to those elicited by immunisation. Vaccines are a useful
tool to probe the infant immune system, circumventing the need to challenge with the
bacterium itself, as has been shown for viral pathogens such as influenza [133–135].
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4. Measuring Vaccine-Induced Cellular Responses in Humans
4.1. How Do We Measure T-Cell Responses in the Blood?
Proliferation and clonal expansion of the antigen-specific T-cell population is crucial to
orchestrating the development of protective immunity and immunological memory [136].
Defining vaccine-induced T-cell immunity, however, is complex and hampered by practical
and biological challenges [137–140]. In humans, the primary source of T-cells is from
the blood, which does not always accurately recapitulate immune events occurring in
the tissue or mucosa. Furthermore, their very low frequency in peripheral blood means
that easy enumeration and phenotypical characterisation of the total pool is difficult,
requiring the processing of high cell numbers and/or highly specific analytical methods;
frequencies of antigen-specific T-cells within the human memory repertoire are usually in
the range between 10−5 and 5% [46]. This is further compounded by small sample volumes,
particularly in infants.
Up until recently, limited parameters of the pertussis-specific T-cell response have been
analysed, which may in part explain previous conflicting data. However, characterising the
T-helper cell subset, memory phenotype, central/effector phenotype, homing/chemokine
markers, cytokine release, T-cell repertoire and T-cell receptor sequence are all crucial to
our understanding of the multidimensional pertussis-specific T-cell response.
4.1.1. Traditional Methods
Two T-cell parameters have conventionally been measured: cell proliferation and/or
cytokine production. The classical and most commonly used method to determine T-cell
proliferative capacity is based on measuring titrated, radioactively-labelled thymidine
([3H]TdR) incorporation into the DNA of proliferating cells using a scintillation counter.
The [3H]TdR assay is a simple and easy method to perform, with relatively high throughput;
however, it requires radioactive facilities and specialised management of waste which may
not be available [141]. An alternative is to determine incorporation of the pyrimidine
analogue, 5-bromo-2′-deoxyuridine (BrdU) by peroxidase-labelled detection antibody
using enzyme-linked immunosorbent assay (ELISA) [142].
The enzyme-linked immunospot (ELISpot) is also high throughput–friendly, con-
ventional technique to quantify and measure antigen-specific T-cell responses to vaccine
antigens at a single cell level that relies in their ability to produce cytokines in response to
in-vitro antigen recall (after an overnight culture for effector memory cells or several days
for central memory). It involves stimulating PBMCs with antigen(s) of interest seeded in
tri- or duplicates on 96-well ELISpot plates coated with an anti-cytokine capture antibody.
Cytokines produced by antigen-specific T-cells bind to the capture antibody and are de-
tected using a biotinylated detection cytokine-specific antibody and enzyme-conjugated
streptavidin and a chromogenic development substrate. This method is highly sensitive
(cells producing fewer than 100 cytokine molecules can be detected) and the lower limit of
detection can be under ten cytokine-producing cells per million PBMCs) [143,144]. Unlike
an ELISpot assay, FluoroSpot can detect secretion of more than one cytokine simultaneously
in the same sample using fluorescence instead of chromogenic detection [145].
The major disadvantages of these assays are limitations in the number of param-
eters to be investigated, lack of phenotypic information, and preferential detection of
effector cells. When combined, this likely results in an underestimation of the total antigen-
specific T-cell response. Moreover, the contribution of each cell population to the measured
ELISpot/Fluorospot response is unclear.
4.1.2. Flow-Cytometry Methods
Several flow-cytometric readouts for the direct detection of rare antigen-specific T-cells
have been described in recent years (and used in pertussis vaccine studies), measuring
(a) cell proliferation (b) intracellular cytokine release staining (ICS) (c) peptide-MHC-II
tetramer staining (d) activation-induced markers (AIM). The advantages of these assays
are that they allow co-staining with other markers, enabling identification of cellular
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sub-populations according to phenotypic and functional characteristics, amplifying the
information to be acquired from a single readout [146].
(a) Novel proliferation assays: Classical proliferation assays have largely been replaced by
flow-cytometric readouts. Examples include fluorescent dye dilution assays, using
CFSE or derivative dyes, and assays that detect BrdU by fluorochrome-conjugated
antibody staining [142,147]. Proliferation dyes diffuse easily into cells and bind
covalently to the amino groups of intracellular proteins; since the dyes are divided
equally between daughter cells the number of cell divisions of the proliferating
cells can be visualised, thus allowing the theoretical enumeration of antigen-specific
cells [136,141]. Expression of Ki67, a nuclear protein that coordinates regulation of cell
division, is also increasingly being used to measure specific T-cell responses induced
by pertussis vaccination, including longitudinal monitoring [148].
(b) Intracellular staining (ICS) is a versatile method used to analyse cytokine production
at a single-cell level by flow cytometry, although it is less sensitive than ELISpot [149].
Blood or PBMCs are stimulated with the antigen(s) of interest and a transport in-
hibitor (e.g., BFA or monensin) is added for several hours to block secretion of the
produced cytokines, thus allowing detection. Stimulated cells are then stained with
fluorescently-labelled antibodies targeting surface markers then fixed, permeabilised
and stained with anti-cytokine antibodies, before flow-cytometric analysis. This al-
lows detailed phenotypic and functional analysis of pertussis-specific T-cell subsets
and diverse differentiation pathways. Polyfunctionality, i.e., the ability of a cell to
produce >1 cytokine, is also measured [150,151]. Technological advancements have
enabled increasingly higher numbers of parameters to be assessed, although they
must be pre-determined which can skew the response detected; given that standard
panels in clinical trials often use IFN-γ, IL-2 and TNFα (and IL-4 can be difficult
to detect), a more Th1-biased response may be established, which is particularly
concerning when characterising vaccine-induced Th-immunity in pertussis vaccine
research, in which establishing the ratio of different antigen-specific Th-profiles is
important [138,152]. Furthermore, some memory cells may not secrete detectable
levels of cytokines, especially the central compared to effector memory CD4+ popu-
lation which develops at later time points after infection or vaccination [152]. Other
drawbacks of this method include signal-to-noise ratio and nonspecific binding [139].
(c) Peptide-MHC-II tetramer staining: MHC tetramers are based on the structural features
of the T-cell receptor and consist of 4 MHC molecules which are associated with
a specific peptide/epitope [153]; the complex is bound to a fluorochrome, thereby
enabling the direct visualisation, quantification and phenotypic characterisation of
antigen-specific T-cells using flow-cytometry, following both pertussis infection and
vaccination [139,153] This method, however, requires prior knowledge of the MHC
alleles of the donor (particularly challenging in a LMIC) and relevant antigenic epi-
topes; moreover, it only gives limited and preselected insight into the heterogeneous
T-cell populations specific for a certain antigen.
(d) Activation-induced marker (AIM) assays: More recently, techniques have been devel-
oped that do not require prior knowledge of MHC alleles nor focus on single cy-
tokine responses but instead assess T-cell specificity irrespective of their functionality.
Antigen-specificity is defined based on the upregulation of T-cell-receptor-stimulated
surface markers, termed activation-induced markers (AIM), upon overnight antigen
recall of either whole blood [154] or PBMCs [152,155], without the need for fixation
and permeabilisation of cells for ICS.
Specific combinations of AIM markers used to detect antigen-specific CD4+ in per-
tussis vaccine research to date include CD40L (also termed CD154) alone or co-expressed
with CD69 and, most commonly, co-expression of OX40 plus CD25; the latter has been
used to identify the maximal antigen-specific response, with or without PDL1 to discrim-
inate antigen-responsive T-reg cells which upregulate CD25 upon antigen stimulation,
a potentially important compartment that may contribute to underlying immunological
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differences between aP and wP vaccines, as discussed previously [152,155–158]. In parallel,
AIM combinations, such as CD107a and CD137 (4-1BB), or OX40 and CD25, have been
used to identify antigen-specific CD8+ T-cells [156,159]. Comparisons of combinations
have demonstrated that these assays have high concordance and identify distinct but over-
lapping populations of antigen-specific CD4+ T-cells; bystander activation was confirmed
to cause minimal background [152].
Furthermore, as well as capturing the total pool of pertussis-specific T-cells, AIM
assays are particularly beneficial in the identification of antigen-specific Tfh. This cell
population is difficult to identify by cytokine production (ICS), given that their function
is to primarily help adjacent germinal centre B-cells via cognate interaction, with limited
cytokine secretion compared to other Th-cell types [155].
4.1.3. Methods to Enrich Antigen-Specific T-Cells
Despite their significant advantages, these flow-cytometric technologies are limited
by the number of cells per sample that can be acquired in reasonable time (105–106) as
well as by the natural and/or technological background of the assay, which is typically
between 0.01 and 0.1%. Sufficient target events are required to be able to identify small
subsets with high statistical significance [160]. As such, methods have been developed to
further increase or enrich the antigen-specific T-cell pool.
Firstly, in-vitro re-stimulation and development of libraries of polyclonal expanded
memory CD4+ T-cells enables greater sensitivity to detect and enumerate rare antigen-
specific T-cells; however, extended culture may alter the phenotype or function of re-
sponding T-cells, particularly activation, memory and homing markers [161]. The most
recent successful strategy, therefore, has been to assess responses ex-vivo (following short
overnight stimulation), by using pools of different epitopes or peptides, so that the overall
frequency of responding cells is enhanced. This approach is particularly effective when
combined with ELISpots or AIM assays described above and is critical to analysing small
volume samples. A megapool approach is applied which consists of deconvoluting re-
sponses to large numbers of peptides of overlapping sequences, previously successful
in pertussis vaccine studies as well as, more recently, to interrogate T-cell immunity to
SARS-CoV-2 [46,47,109,162].
Secondly, the rapid antigen-reactive T-cell enrichment (ARTE) approach utilises
magnetic-bead enrichment of TCR-activated T-cells that have upregulated the costim-
ulatory molecule CD154 (CD40L) to assess human antigen-specific CD4+ T-cells ex-vivo.
This relies on magnetic labelling of cells prior to separation in a magnetic field [157,158,160].
A CD40-blocking antibody needs to be added into the culture to prevent downregulation
of CD154 expression. Furthermore, this type of enrichment can be combined with tetramer
technology and used to identify rare peptide MHC-multimer–labelled cells from large
sample sizes [153].
4.1.4. Higher Throughput Technologies: Multidimensional Flow or Mass Cytometry
Multicolour fluorescence-based flow cytometry is more user and equipment friendly
than mass cytometry, with easier access to antibodies, and it allows recovery of the cells
by single-cell sorting. Enhanced flow cytometry with imaging capabilities enables the
determination of cell morphology, as well as the spatial localisation of the protein molecules
within a single cell. Advances in both microfluidics and digital PCR have improved the
efficiency of single-cell sorting and allowed multiplexed gene detection at the single-cell
level [149].
Nevertheless, flow cytometry is inherently limited by the number of parameters that
can be simultaneously analysed. Recently, the advent of mass cytometry by time-of-flight
(CyTOF) has facilitated deep interrogation of a large number of single-cell protein expres-
sion simultaneously [163,164]. It is based on the concept of using heavy-metal isotopes to
label antibodies followed by mass spectrometry as the readout, in lieu of fluorochromes
and light detection. As such, it avoids significant spillover between detector channels,
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which is a key challenge in fluorescence flow cytometry. High-dimensional phenotypic data
can be visualised by combining CyTOF with algorithms such as visualisation of stochastic
neighbor embed (viSNE) and spanning-tree progression analysis of density-normalized
events (SPADE) [140,163]. As the throughput on CyTOF is lower than conventional flow
cytometry, it can be coupled with magnetic bead enrichment for the sensitive analysis of
rare antigen-specific T-cells, based on their expression of CD154+/−CD69, as described
previously [164].
4.1.5. Omics’ Technologies
Accumulating data from existing technologies demonstrates that there is consider-
able, previously underappreciated, heterogeneity in T-cell responses; additional pathogen-
related functional patterns emerge not necessarily associated with the dominant Th1/2/17
classification. Epitope-specific T-cells can be further characterised in-depth by transcrip-
tomic profiling that uses deep-sequencing technologies, including bulk RNA-seq or single-
cell RNA-seq(scRNA-seq) [46,146].
Transcriptome signatures for aP versus wP vaccine responses are being defined in
both animal models and human studies, characterising both innate and adaptive immune
compartments [109,165]. Multiple key factors in Th-differentiation, including transcription
factors, cytokines, and receptors, have been identified within the differentially expressed
genes [165]. A recent murine study aimed to elucidate the kinetics of the protective
immune response evolving after experimental Bp infection in mice, including activation of
particular transcription factors and cell markers; using a systems approach they provided
detailed insight into molecular and cellular sequence of events connecting different phases
(innate, bridging and adaptive) of the immune responses, detecting a prolonged acute
phase response, broad pathogen recognition, and early gene signatures of subsequent T-cell
recruitment in the lungs. In addition, signatures preceding the local generation of Th1 and
Th17 cells as well as IgA in the lung were identified [166].
Example human studies include the characterisation of transcriptomic profiles of
pertussis-specific CD4+ T-cells from aP- versus wP-primed donors, in order to shed light
on the nature of the key differences between the infant vaccines [109]. Differential gene
expression was noted which corroborated flow-cytometry findings at the protein level
(including the upregulation of the IL-9 gene in wP versus IL-5, IL-13, and TGF-β genes in aP
donors, described previously). Moreover, the team applied Gene Set Enrichment Analysis
(GSEA), a computational method that determines whether certain biological functions
are significantly represented in the input group of genes, as well as Ingenuity Pathway
Analysis (IPA) to obtain additional functional insights; for example, this helped to establish
that mitosis and cell-cycle progression genes that promote cell division were increased
in wP samples. Their results suggested that aP versus wP priming is associated with
alterations in specific T-cell subsets (as suggested by the differential polarisation) and in cell
proliferation (consistent with lack of in-vivo boost in aP-primed donors) [109]. Furthermore,
White et al. also used an unbiased systems biology approach to elucidate Th2-associated
responses to aP infant vaccines via gene co-expression network analysis, which identifies
genes that function co-ordinately in complex pathways, comparing to other vaccines.
They demonstrated that following TdaP, potentially antagonistic Th1-/IFN-associated and
Th2-associated gene networks coexist in an apparent state of dynamic equilibrium [167].
Next-generation OMV vaccine responses are being interrogated using a similar systems
approach; subcutaneous and pulmonary immunisation routes were recently compared in
mice, combining analysis of innate responses and induction of mucosal and systemic T and
B-cell responses (including CD103+ T-cells) [168].
In comparison with bulk RNA-seq, scRNA-seq is a more powerful tool to investigate
vaccine-induced cellular heterogeneity and identify novel subpopulations, by applying
a granular and unbiased approach [169,170]. Combined TCR-transcriptome analysis, for
example, has been applied successfully to interrogate yellow fever virus vaccine-reactive T-
cells [171]. Delving further into the transcriptome of single-cells using RNA-seq is likely to
Vaccines 2021, 9, 877 16 of 41
reveal the fine-specificity of cellular events such as alternative splicing (i.e., splice variants)
and allele-specific expression, and will also define the roles of new genes [46,146]. Detailed
analysis of clonally-related antigen-specific T-cells using scRNA-seq provides information
on pathways of differentiation of memory T-cells; using pseudotime tools, trajectories of
T-cell differentiation can also be inferred [172,173]. These technologies have advanced
substantially in the field of cancer immunology: vaccine research is just catching up.
4.2. How Do We Integrate This with Knowledge of T-Cell Epitopes?
4.2.1. Epitope Mapping
An important aspect when interrogating antigen-specific T-cell populations is to
characterise the corresponding antigen targets and most immunodominant T-cell epitopes.
To date, T-cell epitopes elicited by either natural Bp infection or wP immunisation have
not been comprehensively defined [53]. Indeed, one of the key problems in elucidating
the differences between aP compared to wP vaccines has been the lack of an appropriate
antigen to tease out antigen-specific cells. The most common antigens used have been either
the 5 key proteins in the aP vaccine or pertussis lysate, although the latter induces strong
non-specific background responses due to the presence of Bp-specific as well as common
bacterial antigens and innate receptor triggering ligands [150]. More recently, ‘megapools’
of overlapping peptides derived from the aP vaccine have been developed, as described
in Section 4.1.3 [37,109]. However, a reliable pool of immunodominant epitopes derived
from the wP vaccine is yet to be established, although is currently in the pipeline, based
on bioinformatic epitope predictions and a full-scale genome-wide mapping of memory
T-cell reactivity (using ex-vivo AIM readouts) to Bp antigens in humans [47]. Indeed, a
similar genome-wide mapping of T-cell responses to Mycobacterial tuberculosis antigens was
recently accomplished successfully [46]. An alternative in-silico approach can be applied to
identify and modify T-cell epitopes in pertussis antigens that are cross-reactive with human
sequences (and potentially tolerance-inducing); proteins with reduced tolerogenicity have
improved vaccine potency in preclinical models [174].
Defining novel targets associated with T-cell reactivity and understanding patterns of
epitope sequence variation throughout the population is also of considerable interest given
the hypothesis that the switch from wP to aP generated a response that is less diverse,
thereby creating an opportunity for Bp to escape vaccine responses. For example, Bart et al.
identified a total of 471 coding SNPs from pre-vaccination strains. Precise mapping of
epitopes that are not also targets of immune responses and a comparison of mutation rates
of epitopes versus non-epitopes for both vaccines will further elucidate if the observed
genetic variability of circulating Bp strains is indeed a result of T-cell immune pressure [175].
Beyond characterising epitope patterns, studies to determine HLA restriction to certain
epitopes, associated HLA polymorphisms and binding promiscuity (which may vary by
participant group/setting), HLA binding affinity and analysis of epitope conservation
would also be informative [46].
4.2.2. Combine with T-Cell Receptor Sequencing
TCRs dictate the antigen-specificity of T-cells through their interactions with peptide
presented within MHC molecules. Epitope-associated TCR repertoires can therefore be
defined by TCR sequencing [146]; more recently, using scRNAseq, both alpha and beta
chains can be sequenced simultaneously. This enables robust investigation of the common
features of TCRs that are specific for a particular epitope and identification of determinants
that may predict specificity [172]. Knowledge of key TCR sequences can subsequently
be integrated with understanding the functional, phenotypic and transcriptomic T-cell
profiles related to recognition of specific epitopes, particularly novel targets identified in
wP vaccines, as compared to the ones currently included in the aP vaccine.
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4.3. How Do We Measure T-Cell Responses in the Mucosa?
To date our knowledge of vaccine-induced mucosal immunity has relied on animal
models, given the practical difficulties in studying the mucosal antigen-specific T-cell
compartment in humans. Unfortunately, immunological findings in animals often fail to
translate fully to humans.
Early studies optimising AIM T-cell readouts, specifically in the context of defining
Tfh responses, compared results in both blood and lymphoid tissue from adult donors
who were undergoing tonsillectomy [155]. A more common and less invasive method
to sample mucosal cells is a nasopharyngeal wash, although the luminal cell population
can vary significantly from intra-mucosal cell populations. Recently, nasal curettes or
brushes have been used to collect epithelial cells from the inferior turbinate for culture,
gene expression and phenotypic/functional analysis using flow cytometry [176]. However,
these techniques are challenging and less well-tolerated in infants.
Instead, measuring cytokine and other soluble immune mediator levels in either na-
sopharyngeal wash or mucosal lining fluid (MLF) provides a useful surrogate of mucosal
CMI [177]. MLF is produced by the nasal inferior turbinate (i.e., upper airway ciliated
epithelium) and can be collected using a unique ‘Nasosorption’ device, consisting of an
absorptive matrix which acts like blotting paper; it has been used previously with suc-
cess in the context of allergens, pathogens, challenge models or vaccine studies [178–181].
Superior cytokine detection was confirmed with absorptive matrices compared to nasopha-
ryngeal wash [176]. One limitation of using this cytokine-based approach, however, is
that the secreting cells cannot be characterised, and the readout may be susceptible to
background ‘noise’, including numerous confounding factors that shape the upper airway
immune milieu.
Furthermore, recent interest in TRMs has led to an increased focus on homing mark-
ers to capture these mucosal cells following activation as they migrate to their tissue of
interest [26,43,182]. To date, homing markers have been established for gut and lower res-
piratory tissue but less is known about the upper airway. CD69 and CD103 are thought to
be key lung homing markers, however, CD69 is also upregulated following TCR activation
(AIM) [26].
Finally, the CHIM will contribute immensely to our knowledge and understanding
of Bp-specific mucosal immunity and how it correlates to systemic responses in humans,
following different immune challenges.
5. Which Factors May Affect T-Cell-Mediated Immunity to Pertussis
Infant Vaccinations?
Multiple factors may shape CMI to pertussis immunisation throughout infancy, child-
hood and adolescence and need to be taken into account when analysing CMI as well as
designing and testing next-generation vaccines. A detailed characterisation of all potential
influencing factors, however, is beyond the scope of this review but has been explored by
other authors and in the context of different vaccines [183].
5.1. Vaccine-Related Factors
The type of pertussis vaccine delivery (mucosal versus parenteral), formulation (anti-
gen type, strain, dose and adjuvant content), platform and schedule are all important in
modulating the antigen-specific cellular compartment. Strategies to harness these factors
to improve vaccine-induced responses will be discussed in the final section.
5.2. Host-Related Factors: Intrinsic (Innate)
5.2.1. Age
Data on the effect of age on vaccine-induced T-cell responses are conflicting. On one
hand, no significant difference was found between full-term and preterm infants in their
ability to mount a robust and specific cellular immune response to the administration of
the primary course of pertussis vaccines [184]. Other studies, however, have observed
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quantitatively lower and/or qualitatively suboptimal long-term cellular responses in vac-
cinated pre-term (especially under 31 weeks) compared to term infants [16]. Indeed, it is
well established that immune ontogeny in early infancy has distinct developmental restric-
tions or functional adaptations, particularly when compared to older children [134,185].
Impaired CD4+ and CD8+ T-cell frequency and function is observed, such as after pri-
mary immunisation, with marked Th2 skewing. This can be explained by epigenetic
processes, lower soluble factors, and suboptimal frequency and distinct functional capacity
of antigen-presenting cells [133,186]. Diminished B-cell interaction with T-cells is also ob-
served, which subsequently affects germinal centre responses and B-cell maturation [187].
Indeed, in comparison to term infants, preterm infants have significantly lower pertussis
antibody levels following both completion of the primary immunisation course and, in
some studies, even subsequent pertussis boosters [188–190]; this may be partly driven by
T-cell dependent mechanisms.
5.2.2. Sex
The vaccine response profile can vary according to sex, partially explained by differ-
entially elevated levels of gonadotropins and sex hormones in male and female infants
in the first few months of life, usually decreasing by 1-year of age [183,191]. Further-
more, a number of immune response genes and microRNAs are also encoded on the
X-chromosome [192]. There is a paucity of data to date, however, on the impact of sex on
pertussis vaccine immunogenicity.
5.2.3. Genetics
Various ethnic groups living in the same location have different vaccine responses
suggesting a genetic influence on vaccine responses [183,193]. Studies of twins estimated
the degree of heritability following aP immunisation to be 53–65% for cellular responses,
primarily IFN-γ and IL-13 induction [193–195]. Polymorphisms in critical genes signif-
icantly modulate CMI to infant vaccines, including major histocompatibility complex
(MHC) genes as well as non-MHC factors, such as pattern recognition receptors, blood
group antigens and genes involved in key immune signalling pathways [196–200]. For
example, a Dutch infant cohort study demonstrated the association of a single-nucleotide
polymorphism in TLR4 (role described in Section 2) with magnitude of PT-IgG following
wP vaccination [201].
5.3. Host-Related Factors: Intrinsic (Acquired)
5.3.1. Microbiome
Studies are increasingly showing a mutualistic relationship between vaccine responses
and the intestinal microbiota, although data in humans is only recently emerging [202–204].
Vaccine-induced protection against Bp was reduced in azithromycin-treated mice, asso-
ciated with impaired CD4+ T-cell memory, including lower numbers of lung TRMs and
IL-17-production, as well as CD49d expression on splenic CD4+ T-cells after challenge [205].
Zhang et al. also showed that antibiotic-mediated dysbiosis in the murine intestinal mi-
crobiome resulted in immunomodulation, with increased susceptibility to Bp infection
initially. This was associated with a significant deficiency in systemic Ig, IgG1 and IgG2a an-
tibody responses as well as impact on the short-lived plasma-cell and Bm recall responses,
CD4+ T-cell generation and PD-1 expression on CD4+ T-cells (likely perturbing plasma-cell
differentiation) [206].
The contribution of the respiratory microbiome (nasopharynx and/or lung), however,
is unclear [207–209]. There is minimal data in the context of pertussis immunization. One
murine study on Bp infection demonstrated the important role of resident nasal microbiota;
delivering broad-spectrum antibiotic treatment before Bp inoculation enabled it to effi-
ciently colonise the nasal cavity, while subsequent reintroduction of single Staphylococcus or
Klebsiella species in the nose of the same mice was sufficient to inhibit Bp colonization [210].
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Furthermore, underlying immunological mechanisms remain elusive; changes in the
level of microbially-derived metabolites may activate the innate immune compartment,
further shaped potentially by breast milk components, thereby modulating development
of T-and B-cells [203,211–214]. Pro et al. recently showed that the sequence homology
between antigens and the human microbiome can either dampen (tolerogenic effect, most
dominant) or increase (inflammatory effect) T-cell epitope immunogenicity; this occurs via
molecular mimicry and is partially determined by bacterial genus. It is currently unknown
whether Bp antigens and epitopes that share significant homology to human microbiota
might be preferentially recognised or conversely tolerised and, therefore, how this might
affect T-cell-mediated vaccine immunogenicity [215].
Conversely, changes in the local immune milieu induced by vaccines may shape
the upper airway microbiome itself, thereby affecting the susceptibility against infective
respiratory pathogens, potentially including colonisation and infection by Bp [216]. In the
context of pneumococcal conjugate vaccines, different serotype coverage results in varying
diversity and stability of the microbiota composition [216].
5.3.2. Co-Morbidities and Malnutrition
The condition of the host, including primary and acquired immunodeficiency (e.g., HIV
and immunosuppressive therapies), evolving infections (e.g., viruses, malaria, helminths) and
chronic illness may impact vaccine-induced CMI [183,217]. Chronic CMV or EBV infections
are prevalent in the first year of life, particularly in LMICs. The former was associated with
very high frequencies of highly differentiated CD8+ and CD4+ T-cells in early life as well
as a reduction in antigen-specific antibodies and limited memory CD4+ IFN-γ responses
following measles vaccination [217,218]. Further work in the context of pertussis immuni-
sation is warranted. Other studies, however, have found no association between low level
of pertussis antigen-induced IFN-γ secretion and certain comorbidities, including very low
infant birth weight, severe infections, corticosteroid treatment or the administration of gamma-
globulins [184]. Furthermore, nutritional status (general malnutrition or vitamins A/D, zinc
and iron levels) and the use of micronutrients at the time of immunisation may also play
a role in the timing, quality and duration of infant vaccine responses [219–222]. Indeed, a
2014 Senegalese study demonstrated that birth season and undernutrition modulated chil-
dren’s humoral response to pertussis toxin, which may be T-cell dependent, although CMI
was not evaluated [223]. Data is heterogeneous, however, with generally poor quality of
evidence [220].
5.4. Host-Related Factors: Extrinsic
5.4.1. Interactions with Other Neonatal/Infant Vaccines
Recently, there has been growing interest in the ‘non-specific effects’ (NSE) of new-
born, infant or even maternal vaccinations, whereby they may confer protection against
pathogens unrelated to their original target and therefore have a broader impact on in-
fant health [222,224,225]. Although not fully understood, two underlying immunological
mechanisms have been proposed: ‘trained innate immunity’ and ‘heterologous immunity’.
The former describes the ability of the innate system to generate immunological memory,
mediated by epigenetic and metabolic reprogramming, and therefore be ‘trained’ to pro-
vide partial protection against subsequent infections [226,227]. The latter describes the
effects on the adaptive immune system, primarily due to T-cell-mediated cross-reactivity
between vaccine-related and -unrelated antigens [228,229]. Neonatal BCG, for example,
has been hypothesised to provide an immune priming benefit across different settings,
by modulating not only vaccine-specific responses but also heterologous T-cell immunity
to off-target antigens (specifically Expanded programme on Immunisation [EPI] vaccines
such as dTaP/dTwP) [230]. Moreover, several vaccines potentially alter antibody responses
to unrelated antigens indicating an effect on B-cell function too.
Conversely, there is an ongoing debate whether neonatal or infant vaccines may in
fact facilitate the development of immune cell hypo-responsiveness instead, particularly
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when challenged with either the same antigen (‘immune paralysis/tolerance’) and/or
concomitant antigens (‘vaccine or bystander interference’) in subsequent infant immunisa-
tion schedules [134,228]. Potential interference will, therefore, need to be considered for
any novel next-generation pertussis vaccines that may be introduced in the future, either
alongside existing EPI vaccines or combined into multivalent formulations [231].
5.4.2. Maternal Factors
Maternal pertussis immunisation programmes are being introduced globally, partic-
ularly in high-income settings [232]. Vaccine-induced maternal antibody is transferred
across the placenta or in breast milk and may interfere with subsequent infant vaccine
responses. Most findings to date have focussed on the impact on the infant humoral
compartment, although underlying mechanisms are not fully understood and the clinical
implications have yet to be fully elucidated, particularly given the lack of a CoP [233,234].
A recent 2017 meta-analysis combined the serological data from 32 randomised-control
trials conducted in 17 countries on a total of 7630 infants, concluding that antigen-specific
maternal antibody inhibits infant antibody responses to priming vaccines and that these
effects could be long-term as they are not always abolished by the administration of a
booster dose; this includes responses to PT, FHA and PRN [235]. A recent study, how-
ever, showed that maternal antibodies may similarly modulate vaccine-specific cellular
compartment in infants, for example, by limiting the expansion of Tfh cells and thus damp-
ening germinal centre output [236]. Findings are scarce and inconsistent, however, with
other studies demonstrating that maternal vaccination does not affect natural infection- or
vaccine-induced infant CMI [237,238].
Beyond this, evidence is now emerging that the fetal and subsequently infant im-
mune system may be shaped by maternal vaccination through more than just the passive
immunity provided via antibody transfer [232]. One possible—albeit poorly understood—
mechanism is maternal ‘microchimerism’ (MMC), which occurs secondary to low frequency,
bi-directional migration of cells via the transplacental (and possibly breast-milk) route;
MMC may play a role in neonatal immunomodulation, particularly maturation of the T-cell
response [239,240]. These cells express non-inherited maternal antigens and can persist in
the offspring long-term, particularly in T-cell or TRM compartments [234]; it is estimated
that up to 1 in 5000 PBMCs may be of maternal origin [241]. Similarly, limited animal ex-
periments and few human-based observations suggest that maternal immune cells can also
be detected in breast milk and may traffic to infant tissues through gut mucosae [242,243].
Secondly, the fetus may be sensitised in utero, both qualitatively and quantitively, to
infection- and non-infection-derived antigens which the mother has encountered during
pregnancy, either as free antigens or antigen-antibody complexes or, potentially, antigen-
loaded vesicles [232,244–247]. This may alter infant immunity, susceptibility to later
childhood infections, vaccine responses and development of immunopathological dis-
orders. ‘In-utero priming’ was first proposed in neonates born to infected mothers, who
are exposed to pathogens but uninfected themselves [246,248]. For example, infants of
helminth-infected mothers are exposed to parasite-derived products that seem to cross the
placenta and potentially prime or tolerate the fetal immune response to parasite-specific
as well as unrelated antigens [249,250]. This early exposure may have long-term effects
on the child’s immune system, including their CMI to pertussis childhood vaccines [249].
To date, however, there has been no robust, consistent evidence that vaccine-induced
(including pertussis) immune responses of infants are strongly suppressed or affected by
the helminth infection status of the mother [249,251–253]. In fact, strongyloidiasis was
associated with enhanced responses to PT [251]. Similarly, empiric treatment of mothers
with antihelminths (e.g. albendazole or praziquantel) during pregnancy does not influence
infant responses to pertussis or other EPI vaccines [249,251–253]. Other maternal infec-
tions, such as malaria or HIV, may also play a key role in eliciting immune dysfunction in
young infants, particularly in LMICs [254]. Despite comparable pertussis-specific T-cell
proliferation between the two infant groups, HIV exposure significantly diminished mea-
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surable CD4+ and CD8+cytokine polyfunctionality in response to Bp stimulation [255].
These differences may be due to in-utero perturbation of the TCR repertoire secondary to
maternal antigen exposure, such as HIV and opportunistic pathogens, or anti-retroviral
therapy, as well as chronic immune activation and inflammation [255–257].
Although controversial, in-utero priming may also occur following maternal immuni-
sation during pregnancy, as suggested by the presence of vaccine antigen-specific B-cell
and memory-T-cell responses in cord blood in some studies, assumed to be secondary
to activation of the fetal adaptive immune cell compartment [258,259]. This has been
demonstrated following maternal influenza and tetanus vaccination, although there is
little data following pertussis immunisation. How this may relate to and modulate sub-
sequent infant CMI to pertussis vaccines, both at the systemic and mucosal levels, is yet
to be fully elucidated. Interestingly, maternal MF59-adjuvanted influenza immunisation
was associated with an altered cytokine profile in the nasal mucosa of 4-week-old infants
subsequently, when compared to those born to unvaccinated mothers [260].
Finally, the maternal peri/postnatal microbiome is also thought to contribute to shap-
ing early infant immune development and function, including modulating metabolites that
originate directly from the maternal diet and are transferred to the offspring, potentially
through breast milk [261,262]. Moreover, a recent review concluded that maternal malnu-
trition and subsequent intrauterine macro- and micronutrient deficiency is likely to impair
infant responses to vaccines, even in the presence of nutrient supplementation, although
evidence is limited and/or average quality [263]. There are no current studies relating this
complex interrelationship to subsequent infant vaccine responses (including pertussis).
6. The Future: How Can We Harness Our Knowledge of Cell-Mediated Responses to
Improve the Next-Generation of Pertussis Vaccines?
6.1. Harnessing CMI to Improve Vaccine Testing
Determination of a reliable CoP is an important part of the vaccine development
process and aids progress towards licensure [57]. To date, pertussis vaccine-induced
protection has primarily been measured by ELISAs that quantify total PT-specific antibody
titres [59]; assays that measure functional antibodies (e.g., opsonising, neutralising, serum-
bactericidal) are also important, although poorly standardised [264–266]. Indeed, none
of the current assays are gold standard yet and a clear CoP for pertussis immunity with
a threshold value known to provide clinical protection remains to be established. Given
that CMI plays a key role in the quality and duration of protective immunity to Bp, a
CoP based on accurately enumerating and phenotyping T-cell immunogenicity would be
informative for both preclinical studies and clinical trials, particularly if novel pertussis
vaccines are to capitalise on the T-cell response [58,138]. Identifying appropriate T-cell
parameters has so far been challenging without a clear understanding of the mechanisms
that afford protection. One potential approach may be to determine separate co-CoPs
against infection/colonisation versus symptomatic disease.
Important biological and logistical considerations when running these T-cell assays in
vaccine trials include use of whole blood versus PBMCs; running fresh versus frozen sam-
ples; testing the type and concentration of stimulating antigen plus length of stimulation;
setting up ex-vivo versus in-vitro readouts. Facilitating reproducibility, reducing interlabo-
ratory variability (including operator, reagents and equipment differences across sites) and
standardising and validating T-cell assays (including appropriate cell viability and positive
controls) is crucial, notably in the context of multi-centre randomised control trials which
may include poorly-resourced settings [267]. The ability to obtain T-cell readouts from
cryopreserved cells is particularly important for logistical planning, because it enables
the assay to be run across multiple centres and batching of samples from multiple time
points, improving efficiency and reducing experimental variation (although some markers
may be susceptible to freezing). Vaccine trial sample size calculations are also problematic,
given the paucity of data on infant immunity and heterogeneity in immune responses,
therefore requiring large numbers of recruits to reach statistical significance [7,140,268].
PERtussIS Correlates Of Protection Europe (PERISCOPE) Consortium was established
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in 2016 to address some of these obstacles, by enabling fruitful collaborations between
key academic, public and private stakeholders; by generating robust technologies and
infrastructure for future vaccine development; and by establishing novel, standardised,
validated biomarkers of protective immunity [269].
Antigen-specific T-cell responses in multi-centre vaccine trials are routinely deter-
mined using cytokine-based approaches, such as ELISpot and ICS assays described pre-
viously, avoiding the need for labour-intensive HLA typing. A recent pertussis vaccine
study also characterised the cytokine profile in culture supernatant (using a multiplex
Luminex assay) collected following 24–48 h whole blood stimulation with antigen [150];
although the exact cell-type secreting the cytokines cannot be ascertained, findings corre-
lated well with flow-cytometric readout of ICS run in parallel. This type of supernatant
assay may therefore provide a practical, easily reproducible alternative that can be applied
even in low-technology settings. However, cytokine-based methods likely underestimate
the frequency of the antigen-specific response and their limitations have been described
previously in Section 4.1.
By contrast, the ex-vivo AIM assay provides a comprehensive account of the total
antigen-specific response and could therefore be a valuable tool to establish a clearer
immunological CoP. Practically, AIM assays require only short stimulation, small blood
volumes and can be used with cryopreserved PBMCs. Bowyer et al. have provided the
first in-depth assessment of vaccine-specific CD4+ and CD8+ T-cells using AIM panel
OX40, CD25, PDL1 within a clinical trial setting [152]; in comparison to their ICS readout,
the limit of detection was significantly lower with 2–3 times more antigen-specific T-cells
detected at the peak time point [152]. Further validation, however, is required for the use
of the AIM assay as a primary immunogenicity measure within phase II/III clinical trials
of future vaccine candidates. Recently developed molecular techniques are also being
used to assess immunogenicity in pre-clinical studies, with the potential to be applied
to very small blood volumes in clinical trials as possible CoP. However, their high costs
and requirement for state-of-the-art equipment and expertise currently precludes their
widespread use, particularly in LMICs.
By combining different technologies, we can dissect the frequency, phenotype, and
function of pertussis-specific T-cells in greater detail than previously possible. Flow or mass
cytometric readouts can be combined: for example, AIM/ARTE or MHC tetramers together
with other phenotypic surface markers and ICS. This can further be coupled with single-cell
sorting followed by functional assays and/or transcriptomic or TCR analysis. Longitudinal
characterisation of pertussis vaccine-specific T-cell immunity needs to be done in parallel
with profiling and kinetics of the B-cell, humoral and innate responses. The data that
emerges can subsequently be interrogated using bioinformatic analytical tools, including
machine-learning-based gating algorithms for flow cytometry readouts [170,270,271]. It
is important that relationships are analysed in a biologically plausible way and that data
is collected and combined from different immune interfaces i.e., both peripheral blood
and mucosal samples. A recent systems vaccinology approach combining transcriptomic,
proteomic, cytometric and serologic profiling revealed that, while broad immune signatures
to TdaP booster are shared between aP- and wP-primed individuals, a subset of aP-primed
individuals show divergent response patterns [272]. Furthermore, data on factors that
may affect CMI (discussed in Section 5) should be collected and included in the final
efficacy analysis of pertussis vaccine studies or trials, especially if multiple centres across
settings with differing population cohorts/demographics are involved [267,268]. If found
to be play a significant role, these factors can potentially be modified or interventions
introduced to improve vaccine immunogenicity, efficacy and/or longevity. Analyses must
also consider age-related changes in longitudinal cohorts and include identification of
preterm babies [273].
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6.2. Harnessing CMI to Improve Vaccine Design and Delivery
Multiple strategies have been proposed to harness emerging knowledge of pertussis-
specific vaccine cellular responses in order to develop the next-generation of improved,
longer-lasting infant vaccines. These have been reviewed in-depth elsewhere but are
summarised in Table 1 [1,7,26,43].
Above all, given that pertussis is acquired through the respiratory tract, nasally
administered vaccines that stimulate mucosal immunity may prove more efficacious than
vaccines eliciting solely systemic responses [274,275]. A variety of intranasal pertussis
vaccines have been investigated in recent years along with different adjuvants; the most
promising options include OMV or the live-attenuated BPZE1 vaccines, shown to effectively
induce antigen-specific mucosal CMI and confer protection against both nasal and lung
colonisation (Table 1).
Table 1. Strategies to improve or guide novel infant pertussis vaccine design, including T-cell responses measured and
protection conferred.





and derivatives (e.g., BPZE1f3)
n Immunogenicity confirmed
in mice, baboons, rhesus
macaques and
humans [276–281]
n Currently in clinical
trials (NCT03942406
and NCT0354149).
n Dominant Th1 response:
TNF-α or IFN-y.
n Minimal Th2 (IL-13) or
Th17 (IL-17A) cells detected
in humans vs. Th17
responses in animals
restricted to lung, spleen, or
nasal cavity




n No induction of
BPZE1–specific
CD8+ T-cells
n Increase in circulating
T-follicular-helper (cTfh)




n Protection against both









n Await results in humans
GamLPV (live-attenuated) vaccine
n In humans n Await results.











nasal IgA levels (mainly
directed against Vag8
and LOS).
n Protection against both
lung and nasal colonisation,
potentially preventing
transmission, in mice.
Aerosol delivery of wP vaccine,
no adjuvant [285] (in humans)
n T-cell responses
not assessed
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Table 1. Cont.
Strategy Examples Vaccine-InducedT-Cell Responses Protection Induced
aP only or combined with
IRI-1501




n Compared to convalescent




n Protection against high Bp
burden in upper and lower
respiratory tracts of mice
n Reduced markers
of inflammation
aP mixed with curdlan





n Curdlan binds to dendritic
cells leading to a nuclear
factor κB-mediated
Th17 response
n No increase in TRM cells
observed in the lung
n Increased IL-17; intranasal
mucosal IgA and serum
IgG response
n Adding curdlan does not
improve respiratory Bp
clearance compared to aP
vaccination only
aP mixed with genetically
detoxified Escherichia coli
heat-labile toxin (LT)
n Two mutants: LTK63, lacks
ADP-ribosylating activity
and LTR72, partial activity
(in mice) [288]
n Enhance antigen-specific
serum IgG, secretory IgA,
and local and systemic
T-cell responses,
n LTK63 promotes a mixed
Th1/2 profile
n LTR72, especially at low
dose, selectively enhances
Th2 cells and high IgA and
IgG titers.
n High level of protection
against Bp burden in the
lungs in mice.
aP mixed with LP-GMP,
comprising c-di-GMP, an
intracellular receptor stimulator
of interferon genes (STING)
agonist, and LP1569, a TLR2
agonist from Bp (in mice) [42]
n Synergistically induces
production of IFN-β, IL-12
and IL-23, and maturation
of dendritic cells.





immunity against Bp nasal
colonisation as well as lung
infection for at least
10 months.
Bacterium-like particles (act as
adjuvant) carrying pertussis
antigens (in mice) [289]
n T-cell responses
not assessed
n Antigen-specific IgG and
IgA induced in mice





aP with genetically detoxified PT
(PTgen) administered using
Viaskin® epicutaneous patches on
days 0 and 14, followed by dTaP
on day 42 (in humans) [290]
n Targets antigens to
Langerhans cells
n Increased anti-PT IgG and
neutralising antibodies
n T-cell responses not
directly assessed
n Not assessed
Outer membrane vesicle (OMV)
vaccine [282,283,291]
n Non-replicating (in mice)




n Poor induction of mucosal
immunity and
respiratory TRMs.
n Protection against Bp
burden in lungs
n No protection against na-
sopharyngeal colonisation.
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Table 1. Cont.
Strategy Examples Vaccine-InducedT-Cell Responses Protection Induced
Vaccine regimen
Additional
neonatal dose followed by
routine infant schedule
Administered as dTaP or aP (in
humans) [292,293]
n Monovalent aP: T-cell









n dTaP-T-cell responses not
assessed specifically.
n Unclear benefit
Priming dose followed by homo-
or heterologous booster
wP primary immunisation
followed by booster dose of aP or
new vaccine (in humans) [294]
n T-cell responses not
assessed specifically
n Mathematical modelling
n Pertussis incidence reduced
by up to 95%
n 96% fewer infections
in neonates
Prime and pull: Systemic priming
followed by nasal boosting [295]
n Potential induction of
systemic then local (via
TRMs) memory immune
response against Bp
n Not investigated in the
context of pertussis to date.
Vaccine type/platform
Live-attenuated BPZE-1 (in mice, non-humanprimates, humans) [276–281]





n Contain multiple Bp






n Inbuilt adjuvant: helps to
activate inflammatory
pathways in murine or
human macrophages
n Intranasal and pulmonary




TRM cells and IgA (not
induced following
subcutaneous route)
n All induce long-lasting
immunity and protection
against Bp burden in lungs
n Only intranasal delivery
protects against upper
airway colonisation









n Induces Th1/Th17 response
n Confers protection against




n Studies in Mycobacterium
Tuberculosis (Mtb): elicited
cells expressing high IL-2
and IL-17A Memory CD4+
T-cells efficiently homed




protection against Mtb in
mice
n Not yet investigated in the
context of Bp in mice or
humans to date
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Table 1. Cont.
Strategy Examples Vaccine-InducedT-Cell Responses Protection Induced
Novel human vaccine types
Recombinant vector vaccines and
nucleic acids (mRNA, DNA)
vaccines (e.g., developed against
SARS-CoV-2 [303,304])
n mRNA SARS-CoV-2 vaccine -
Th1-responses with
RBD-specific CD8+ and CD4+
T-cell expansion.




n Adenovirus vector SARS-CoV-2
vaccine- Th1-biased response
and production of IgG1
and IgG3.
n Not investigated in the




Example includes recombinant PT
mutants e.g., NCT01529645;
NCT02382913 (in humans) [305]
n CMI only assessed in
small subset
n Response induced by
principally Th-1-like
n Weak T cell-specific responses
against PT
n Await further investigation
Add novel antigens to
aP vaccines
Increase number of components
in aP vaccines containing novel
immunodominant epitopes (in
humans) [102,306]
n T-cell immunity not
directly assessed
n 2–3 component vaccines
less effective against disease
(especially mild) than 5
component or wP
Recombinant Adenylate cyclase






n Significantly reduced Bp




BrkA; Vag8 and SphB1 (via
intraperitoneal or subcutaneous
route in mice) [309–311]




suggests BrkA may not affect
Th1/Th2 balance




n Significantly reduced Bp
load in the lower
respiratory tract
n No reduction in bacterial
load in the nasopharynx
Increase antigen dose
Increase amount of fimbriae (Fim2
and Fim3) in licensed
5-component aP (in mice, [312]; in
humans, [102,306])
n Fim may play a role
in infection
n T-cell immunity not directly
assessed in humans
n Preferential induction of Th1
response (IFN-γ) in response
to the PT and FIM antigens




TLR2 agonists e.g., BP1569 or a
synthetic lipopeptide derivative
LP1569 (in mice, [313]);cyclic
dimeric guanosine
monophosphate (CDGM) with Bp
TLR2 agonist (in mice [42])




n LP1569 enhances Th1, Th17,
IgG2a responses
n CDGM: intracellular receptor
stimulator of IFN genes;
promoted Th1/17 responses;












(MPL) or LpxL2 from Neisseria
meningitidis added to aP vaccine
(in mice, [314])
n Little endotoxin activity.
n Reduced eosinophilia in
lungs, reduced ex-vivo
production of IL-4 by
bronchial lymph node cells
and IL-5 by spleen cells,
suggesting reduced type I
hypersensitivity (driven by
Th2 response).
n Enhance protection against
Bp colonisation in the lungs
(vs. alum)
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Table 1. Cont.
Strategy Examples Vaccine-InducedT-Cell Responses Protection Induced
Add novel adjuvants (to
replace alum)
TLR7 agonist e.g., SMIP7 (in mice,
[315]); synthetic TLR7 agonist
combined with PLG nanoparticles
within aP (in mice, [301])
n Promote Th1/17 polarisation
and Ig2a antibody responses
n Enhance protection against
Bp burden in the lungs




polarisation, Ig2a and IgG2c
antibody responses
n Enhance protection against
Bp burden in the lungs (vs.
alum)
Bordetella bronchiseptica
colonization factor A (BcfA)






n Increased IL-17, reduced IL-5,
increased ratio of
IgG2:IgG1 antibodies
n More rapid bacterial
clearance from the lungs
than aP alone
Note: The T-cell responses measured may not necessarily correlate with the protection conferred; further data await. aP, acellular
pertussis; Bp, Bordetella pertussis; CMI, cell-mediated immunity; GMP, granulocyte-monocyte progenitor. Hib, Haemophilus Influenzae B;
LOS, lipooligosaccharide; PLG(A), polylactide-co-glycolide (acid); PT, pertussis toxin; RBD, receptor-binding domain; SARS-CoV-2, severe
acute respiratory syndrome coronavirus 2; sIgA, secretory IgA; SMIP, Small modular immuno-pharmaceuticals; Th, T-helper; TLR, Toll-like
receptor; TRM, tissue-resident memory; wP, whole-cell pertussis.
7. Conclusions
The switch from wP to aP vaccines in the primary infant immunisation schedule is
increasingly considered the most plausible explanation for pertussis resurgence, although
enhanced surveillance and more accurate diagnostic tools have also contributed to the
recent increase in pertussis reporting. Neither vaccine induces the same robust, long-lasting
protection as natural infection, with aP-mediated immunity waning far more rapidly. More-
over, a growing body of evidence from animal models suggests that aP vaccines fail to
prevent upper airway colonisation and induce sterilising mucosal immunity, thereby facili-
tating Bp transmission in fully vaccinated populations by asymptomatic aP-immunised
carriers. This phenomenon is also compounded by aP vaccine-driven emergence of Bp
strains that have modified or absent epitopes, particularly pertactin. Understanding the
underlying mechanisms of waning immunity and inadequate protection against infec-
tion/transmission, both at the systemic and local mucosal levels, will guide the design and
testing of novel, effective immunisation strategies. The ideal pertussis vaccine would be ad-
ministered as one dose intranasally in infancy, eliciting robust, broad and durable mucosal
(and systemic) immunity, including pertussis-specific sIgA(/IgG) alongside Th1/Th17-
polarised TRMs. Protection would thereby be conferred against lung disease as well as
nasopharyngeal colonisation and subsequent transmission. Lessons are being drawn from
previous animal models and human vaccine studies/clinical trials and, more recently, the
controlled human challenge model. A set of assays that effectively and reliably capture
antigen-specific T-cell responses should accompany these evaluations. Standard T-cell
assays measure cell proliferation and/or cytokine secretion, while a new generation of
sensitive and/or high-throughput methods have facilitated direct analysis and character-
isation of rare antigen-specific cell sub-populations, particularly multidimensional flow
cytometry, CyTOF and transcriptomics/genomics technologies. Single-cell analyses have
focused on measuring the quality and breadth of responses, which must be combined with
rigorous mapping of immunodominant T-cell epitopes, as yet unknown but in the pipeline
for wP vaccines. Figure 2 summarises the key gaps in knowledge and avenues for future
research to understand the differences between aP and wP vaccines.
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